Novo Nordisk and Pfizer made their presence known on the first day of the annual ObesityWeek conference. On Tuesday, the large drugmakers escalated their bidding war for Metsera, a Phase 2 biotech creating long-acting injectables and oral treatments for obesity. Both companies increased their offers to acquire Metsera, and a Delaware judge let the dueling continue until at least 3:15 p.m. on Wednesday, when the court could decide whether to grant Pfizer’s request for a temporary restraining order to prevent Metsera from ending its agreement or choosing Novo instead.
Read the full article: ‘Everybody’s Talking About It’: Metsera Bidding War Grips the Obesity Field //
Source: https://endpoints.news/everybodys-talking-about-it-metsera-bidding-war-grips-the-obesity-field/